The short answer
Probably lower-risk than the oral pill, but not risk-free, and not FDA-approved. There is no FDA-approved topical finasteride product. Only two oral formulations carry FDA approval: Propecia (finasteride 1mg, approved 1997) for hair loss and Proscar (finasteride 5mg) for prostate enlargement. What Hims, Keeps, Ro and similar platforms sell as topical sprays, foams, and drops are compounded drugs — mixed to an individual prescription by a pharmacy, never reviewed by the FDA for safety, effectiveness, or manufacturing quality before reaching a customer. In April 2025, the FDA reviewed 32 adverse event reports tied to compounded topical finasteride from 2019 to 2024 — including erectile dysfunction, depression, and suicidal ideation that in most cases persisted after people stopped using it — and issued a formal alert. Separately, the largest real-world safety dataset available, a January 2026 study of over 600,000 users, found side effects were rare and mostly mild. That study was funded and largely authored by Hims & Hers itself, the company selling the product, and a German pharmacology journal has since raised real questions about its methodology. Independent pharmacovigilance data published the same year backs up the directional claim — topical does look safer than oral — while confirming the same category of side effects still shows up, just less often. Both things are true at once.
What "compounded topical finasteride" actually is
Finasteride works by blocking 5-alpha reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT) — the hormone most responsible for shrinking genetically susceptible hair follicles in male pattern baldness. Taken as a daily pill, it's one of only two medications with FDA-approved, decades-long trial evidence for slowing and partially reversing pattern hair loss (the other being minoxidil, which works differently).
What it is not is available as an FDA-approved cream, foam, or spray. When you see products like Hims' Topical Finasteride & Minoxidil Spray (finasteride 0.1%, minoxidil 6%), Keeps' Drop 4-in-1 or topical finasteride-and-minoxidil formulations, or Ro's Mane Spray (finasteride 0.3%, minoxidil 6%, tretinoin 0.025%), you're looking at a compounded drug: a licensed 503A pharmacy mixing the active ingredients into a custom topical formulation against an individual telehealth prescription, rather than an FDA-approved manufacturer producing a standardized, pre-market-reviewed product. Compounding itself is legal and common — it's how, for example, a child gets a liquid version of a pill-only drug — but it means the FDA never evaluated this specific formulation's safety, effectiveness, or purity before it shipped to a customer's door.
What the FDA's April 2025 safety alert actually said
On April 22, 2025, the FDA issued an alert to healthcare providers, compounders, and consumers titled a warning about "potential risks associated with compounded topical finasteride products." It wasn't a recall and it didn't name specific telehealth companies — but it was a direct, formal statement that the agency had seen a safety signal worth flagging.
The alert was built on 32 adverse event reports submitted to the FDA's Adverse Event Reporting System (FAERS) between 2019 and 2024, tied to people using compounded topical finasteride, alone or combined with minoxidil. The reported symptoms were the same category the FDA already lists for oral finasteride: erectile dysfunction, decreased libido, testicular pain, anxiety, depression, suicidal ideation, brain fog, fatigue, and insomnia. The detail the FDA specifically called out: in most of these reports, the symptoms persisted even after the person stopped using the product — the same lingering-symptom pattern long described by post-finasteride syndrome (PFS) advocates for the oral pill.
The FDA's core message wasn't "this definitely causes X in Y% of users" — 32 passively-reported cases can't establish that. It was narrower and, honestly, more important: no compounded topical finasteride product has been evaluated by the FDA for safety, effectiveness, or quality, marketing claims about "lower systemic exposure" aren't the same as FDA-reviewed labeling, and both prescribers and patients should know that before assuming a spray is automatically the safer choice.
The timeline: FDA, EMA, and the research, in order
This story didn't happen in one announcement — it unfolded over about a year, across two regulators and two very differently-funded pieces of research. Reading it in order matters, because each new item changes how you should weigh the one before it.
FDA issues a formal safety alert on compounded topical finasteride, based on 32 adverse event reports (2019–2024) including persistent sexual, mood, and cognitive symptoms after discontinuation.
EMA's PRAC confirms suicidal ideation as a recognized side effect of oral finasteride 1mg, mandating a patient card and label update across the EU. The FDA has taken no equivalent labeling action for oral finasteride, despite petitions from the Post-Finasteride Syndrome Foundation since 2017.
Hims & Hers-funded study publishes in JMIR Dermatology: 638,629 users, only 0.04% self-reported a side effect via messaging, 80.4% satisfaction among the 151,352 who completed a check-in.
German pharmacology journal Deutsche Apotheker Zeitung publicly critiques the underlying trial evidence, flagging a 71% completion rate and no statistically significant difference in subjective hair improvement between topical finasteride, oral finasteride, and placebo. A reminder that a large sample doesn't automatically mean rigorous evidence — especially when the funder and the seller are the same company.
Independent pharmacovigilance analysis (Gupta et al., International Journal of Dermatology) mining FDA's own FAERS database finds topical finasteride generates measurably fewer PFS-type adverse-event signals than oral — but confirms the signal exists. Lower risk, not zero risk.
Notice what's missing from this timeline: an FDA-approved topical finasteride product, and an FDA label change for oral finasteride matching what the EMA already did. Neither has happened as of this writing.
Does "topical" really mean "no systemic risk"? What the absorption data shows
The entire marketing case for topical over oral finasteride rests on one claim: putting it on your scalp instead of swallowing it keeps more of the drug local and less of it in your bloodstream, so fewer systemic side effects like sexual dysfunction. That claim has real support — it's just not the same as zero systemic exposure.
A 2023 pharmacokinetic study (Piraccini et al.) found topical finasteride produces roughly 100-fold lower systemic drug exposure than the oral tablet. Separately, studies on serum DHT suppression — the actual hormonal effect finasteride is designed to produce — show oral finasteride cuts serum DHT by roughly 60–70%, while topical formulations cut it by somewhere around 25–50%, with meaningful variation depending on concentration and which pharmacy compounded it. That's a real, substantial reduction in systemic drug activity. It is not the same as the drug staying entirely on your scalp: some finasteride reaches the bloodstream every time you apply it, and the biological pathway plausibly linked to mood and sexual side effects — reduced levels of allopregnanolone, a neurosteroid finasteride also suppresses — doesn't have a known "safe cutoff" below which it simply can't happen.
Oral finasteride vs. compounded topical finasteride, side by side
Six questions, answered for both forms, using the same sources cited throughout this guide.
| Question | Oral finasteride (Propecia) | Compounded topical finasteride |
|---|---|---|
| Is it FDA-approved? | Yes — Propecia (1mg), approved 1997, plus generics. | No. No topical finasteride product has FDA approval; all are compounded. |
| Typical serum DHT suppression | ≈60–70% | ≈25–50%, varies by concentration and pharmacy |
| Systemic drug exposure vs. oral | Baseline (100%) | ≈100-fold lower (Piraccini et al., 2023) — lower, not zero |
| FAERS adverse-event signal (Gupta et al., 2026) | Detected, more frequent | Detected, measurably less frequent — not absent |
| Manufacturing consistency | Standardized nationwide under FDA cGMP oversight | Varies by which 503A compounding pharmacy mixed it |
| Who sells it | Any pharmacy, standard prescription | Hims, Keeps, Ro and other DTC telehealth platforms, by prescription |
The biggest safety study came from the company selling the product — here's how to read it
On January 22, 2026, JMIR Dermatology published the largest real-world look yet at compounded topical finasteride: a retrospective analysis of 638,629 men prescribed topical finasteride-and-minoxidil through Hims & Hers between April 2021 and April 2025. Of those, 151,352 completed a follow-up check-in around 130 days in. The headline numbers are genuinely reassuring: only 230 users (0.04%) proactively messaged their care team about a side effect at all; sexual dysfunction and depression were each reported by just 0.002% of the full cohort; and 80.4% of people who completed a check-in reported being satisfied with treatment.
Read the fine print, though. Three of the study's authors are full-time Hims & Hers employees and two more are paid advisors to the company; the research itself was funded by Hims & Hers. The authors disclose this, and the journal notes the company had no role in the analysis or the decision to publish — but it's still the seller of the product, grading the safety of its own product, using data collected through its own optional customer-support channel rather than an independent adverse-event registry. Only 23.7% of the full 638,629-person cohort even completed a follow-up check-in, which means the 0.04% side-effect figure is a rate among people who happened to message support, not a rate among everyone who took the drug — a real form of selection bias in either direction.
Shortly after publication, Deutsche Apotheker Zeitung (DAZ), a leading German pharmacy and pharmacology trade journal, published a critical read of the underlying clinical evidence for topical finasteride more broadly, flagging that the pivotal phase III trial behind the topical product had a 71% completion rate, that only 55% of participants provided evaluable photos of results, and that a responder analysis found no statistically significant difference in subjective hair-improvement ratings between topical finasteride (39.8%), oral finasteride (31.0%), and placebo (32.0%). The reviewer's conclusion wasn't that topical finasteride is dangerous — it was that the sample sizes involved are too small to draw firm conclusions about its safety or its effectiveness relative to oral, in either direction.
What the independent data shows
The most useful check on both the FDA's 32-case alert and Hims & Hers' own study is research that comes from neither party. In 2026, a pharmacovigilance study published in the International Journal of Dermatology (Gupta et al.) mined the FDA's own FAERS database directly, using a statistical method called disproportionality analysis to compare 13 post-finasteride-syndrome-type adverse events — erectile dysfunction, decreased libido, suicidal ideation among them — across oral finasteride, topical finasteride, oral dutasteride, and topical dutasteride.
The result lines up with the industry study's direction but not its reassurance level: topical finasteride generated real adverse-event signals for the same PFS-type symptoms, just measurably fewer of them than oral finasteride did, across both timeframes the researchers checked. Topical dutasteride, notably, showed no detectable signal at all in this analysis. The authors' own caveat is worth repeating here too: FAERS is a passive, voluntary reporting system, many reported symptoms are non-specific and could reflect background rates or other causes, and disproportionality analysis detects a statistical signal, not proof of causation. Put together with the FDA alert and the Hims-funded study, the most defensible summary right now is: topical finasteride's risk of systemic side effects looks real but smaller than oral's — not zero, and not yet precisely measured.
Why "compounded" doesn't mean dangerous — but it does mean unreviewed
Compounding pharmacies fall into two regulatory categories. 503A pharmacies compound against an individual patient's prescription, are overseen primarily by state pharmacy boards under USP quality standards, and don't have to register with the FDA. 503B outsourcing facilities — a category Congress created after the 2012 New England Compounding Center meningitis outbreak that killed over 60 people — can produce larger batches, must register with the FDA, and are subject to cGMP inspections closer to those of a standard drug manufacturer. Most telehealth topical finasteride is compounded under the looser 503A model.
None of this means a given bottle of compounded topical finasteride is unsafe. It means the FDA never verified that this specific pharmacy's specific batch contains the concentration it claims, is free of contamination, or is absorbed the same way as the formulation used in whatever study the seller cites — the way it does for an FDA-approved generic drug before that generic ever reaches a pharmacy shelf. Two bottles labeled "finasteride 0.1% topical" from two different compounding pharmacies are not guaranteed to be equivalent in the way two bottles of generic Propecia from two different manufacturers are.
Europe added a suicide-risk warning to finasteride's label. The US hasn't.
In May 2025, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) completed a formal EU-wide safety review and concluded that suicidal ideation should be added as a recognized side effect on the label for finasteride 1mg (the hair-loss dose). The update includes a mandatory patient card inside every 1mg finasteride package, reminding users to seek medical advice if they notice sexual side effects that could be linked to mood changes. Regulators in the UK (MHRA) issued a closely aligned update the same year. The EMA was explicit that finasteride's benefits still outweigh its risks for approved uses — this was a labeling and monitoring change, not a withdrawal.
The FDA has not made an equivalent label change for oral finasteride, despite the Post-Finasteride Syndrome Foundation petitioning the agency on this exact issue since 2017. This isn't evidence the FDA disagrees with the underlying science — regulatory review timelines and evidentiary thresholds genuinely differ between agencies — but it does mean that, as of today, a finasteride user in the EU receives an explicit printed warning about suicidal ideation that a finasteride user in the US, oral or topical, does not.
If you're using — or considering — a telehealth finasteride product
None of the above is a reason to panic, and it isn't an argument that everyone selling compounded topical finasteride is acting in bad faith. It's a reason to be a slightly more informed consumer than the checkout flow assumes you'll be.
- Know exactly what you're taking. Ask your telehealth provider whether your prescription is FDA-approved oral finasteride or a compounded topical formulation, and which pharmacy compounds it — you're entitled to that information.
- Don't wait out sexual, mood, or cognitive symptoms. If you notice erectile dysfunction, low libido, unusual anxiety, depression, or brain fog after starting either form, contact your prescriber promptly rather than assuming it'll resolve on its own — persistence after stopping is exactly what the FDA's alert flagged as the concerning pattern.
- Report side effects, even mild ones. The FDA's entire alert exists because 32 people reported to MedWatch (fda.gov/medwatch). Passive reporting systems undercount events; they don't overcount them.
- Flag a personal or family history of depression or anxiety before starting. This is the population the EMA's mood-related warning specifically concerns.
- A lower systemic-exposure formulation is a reason for cautious optimism, not a reason to skip mentioning symptoms to your prescriber. Lower risk isn't no risk.
- If you want the fully FDA-reviewed option, oral Propecia (or its generics) remains it. That's a real trade-off against topical's apparently lower systemic exposure, not a free upgrade in either direction.
If you want to compare the proven options first
Finasteride, in whichever form, is only one half of the two treatments with real trial evidence behind them. Our hair loss medications guide compares minoxidil and finasteride head-to-head, our genetics guide covers how DHT-sensitivity actually gets inherited, and our free graft and cost calculator can tell you where you stand if medication alone won't be enough — no signup or email required, just an instant estimate.
Frequently asked questions
Is topical finasteride FDA-approved?
No. Only two oral finasteride products are FDA-approved — Propecia (1mg) for hair loss and Proscar (5mg) for prostate enlargement. Every topical finasteride spray, foam, or drop sold by telehealth platforms is a compounded drug that hasn't been reviewed by the FDA for safety, effectiveness, or manufacturing quality.
Is Hims' topical finasteride safe?
The best available evidence points to lower risk than the oral pill, not zero risk. A January 2026 study of 638,629 Hims & Hers users found self-reported side effects in only 0.04% of the full group — but that study was funded and largely authored by Hims & Hers itself. An independent 2026 pharmacovigilance analysis of FDA data found topical finasteride does generate the same category of side-effect signals as oral, just measurably fewer of them.
What did the FDA say about topical finasteride in 2025?
On April 22, 2025, the FDA issued a safety alert based on 32 adverse event reports (2019–2024) tied to compounded topical finasteride, including erectile dysfunction, depression, and suicidal ideation that in most cases persisted after people stopped using the product. It confirmed no topical finasteride product has FDA approval.
Does topical finasteride cause the same side effects as oral finasteride?
The same categories can occur — sexual dysfunction, mood changes, cognitive symptoms — because some of the drug reaches the bloodstream even when applied topically. A 2026 pharmacovigilance study found these signals occur measurably less often with topical than oral, but not never.
Can topical finasteride cause suicidal thoughts?
The FDA's 2025 alert included suicidal ideation among the symptoms reported in its 32-case review of compounded topical finasteride, most of which persisted after discontinuation. Europe's EMA has already added a suicidal-ideation warning to oral finasteride's label; the FDA hasn't made an equivalent change. Anyone with a personal or family history of depression or anxiety should flag it before starting either form.
Is compounded topical finasteride the same as Propecia?
Not exactly. The active ingredient is the same molecule, but the concentration, formulation, and manufacturing oversight differ. Propecia is a standardized, FDA-approved tablet made under cGMP oversight; compounded topical finasteride is mixed to an individual prescription by a pharmacy, and potency and quality can vary from one compounding pharmacy to another.
The bottom line
Compounded topical finasteride sits in a genuinely uncomfortable regulatory gap: sold at scale by well-known, publicly traded telehealth companies, taken by hundreds of thousands of people, and yet never reviewed by the FDA the way the oral pill it's derived from was. The FDA's April 2025 alert, built on 32 adverse event reports, was narrow but legitimate — the symptoms it described, including persistent depression and suicidal ideation, are serious and match a pattern regulators already take seriously for the oral drug. The industry's own January 2026 study, covering over 600,000 users, offers real reassurance about frequency — but it's funded by the seller, methodologically imperfect, and shouldn't be mistaken for independent review. The most trustworthy synthesis, an independent 2026 pharmacovigilance analysis of FDA's own adverse event data, lands in between: topical finasteride appears meaningfully lower-risk than oral, but the same category of serious side effects still shows up, just less often. If you're using it or considering it, that's not a reason to stop — it's a reason to treat the marketing claim of "safer" as directionally true and quantitatively unsettled, and to tell your prescriber about symptoms rather than assuming the spray format means you're exempt from them.
Sources
- U.S. FDA (April 22, 2025). "FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products." fda.gov
- European Medicines Agency (May 2025). "Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines." ema.europa.eu
- Yassky, J., et al. (2026). "Patient Satisfaction, Side Effects, and Other Reactions Reported by Adult Men Prescribed Compounded Topical Finasteride via a National Telehealth Platform: Retrospective Analysis of Real-World Data." JMIR Dermatology. derma.jmir.org / PMC12826577
- Daubitz, T. (2026). Critical review of topical finasteride evidence. Deutsche Apotheker Zeitung, summarized by the Post-Finasteride Syndrome Foundation. pfsfoundation.org
- Gupta, A. K., et al. (2026). "Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System." International Journal of Dermatology, 65, 108-118. onlinelibrary.wiley.com / PubMed 40662444
- Piraccini, B. M., et al. (2023). Pharmacokinetic comparison of topical and oral finasteride systemic exposure. International Journal of Dermatology. onlinelibrary.wiley.com
- MHRA / GOV.UK (2025). "Finasteride and Dutasteride — updated safety warnings for psychiatric side effects and sexual dysfunction." gov.uk
A note on this guide
This article is for general education and doesn't replace individualized medical advice. Finasteride, oral or topical, is a prescription medication with real potential side effects, and decisions about starting, continuing, or stopping it should be made with a licensed prescriber who knows your medical history — not from this article alone. If you experience symptoms after starting finasteride in any form, contact your prescriber and consider reporting to FDA MedWatch at fda.gov/medwatch.